Asarina Pharma raises EURO 7 million
Around 5% of women in fertile age worldwide suffer from Premenstrual Dysphoric Disorder(PMDD), a debilitating condition that prevents sufferers from leading a normal working and social life. Despite the high prevalence of the disease and the severity of its symptoms, there is low awareness of PMDD, and the pharmaceutical industry has so far been unable to meet this medical need.
Asarina’s lead candidate, Sepranolone, could become a game changer. Developed by Professor Torbjörn Bäckström and his team at the University of Umeå (Sweden), and specifically designed for the treatment of PMDD, Sepranolone is the first potential therapy to target the underlying cause of this condition.
For more information please visit